This study is the first in the Turkish population to evaluate serum GAL-1, -3, and − 8 levels together clinically in glioma tumor pathologies with high angiogenic activity, and it sheds light on the role of increased serum galectin levels in the promotion of LGGs to HGG. The gene discussed is LGALS1; the disease is central nervous system cancer.